Bayer could be seeking a major acquisition in the next few years, according to speculative banking sources. Reuters reported the recent wave of industry consolidation could undermine Bayer’s position in markets such as crop protection and animal health. Possible targets for the German company could include veterinary drug firm Zoetis and Pfizer's consumer health business. The planned Dow-DuPont merger creates a more formidable rival for Bayer in both the pesticides and seeds businesses while it also eliminates two potential merger partners. The company, however, is in no rush to overhaul its agriculture business, which is already among the most profitable in the sector with nine-month core earnings margins at more than 26 percent, above BASF, Syngenta and Dow.
Welcome
